Overexpression of RhoGDI2 correlates with the progression and prognosis of pancreatic carcinoma

Yi,Bin; Zhang,Yi; Zhu,Dongming; Zhang,Lifeng; Song,Shiduo; He,Songbing; Zhang,Bing; Li,Dechun; Zhou,Jian

doi:10.3892/or.2015.3707

March-2015 Volume 33 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-2015 Volume 33 Issue 3

Full Size Image

Article

Overexpression of RhoGDI2 correlates with the progression and prognosis of pancreatic carcinoma

Authors:
- Bin Yi
- Yi Zhang
- Dongming Zhu
- Lifeng Zhang
- Shiduo Song
- Songbing He
- Bing Zhang
- Dechun Li
- Jian Zhou
View Affiliations / Copyright

Affiliations: Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China
Pages: 1201-1206
|
Published online on: January 7, 2015

https://doi.org/10.3892/or.2015.3707
Expand metrics +

Abstract

Rho GDP dissociation inhibitor 2 (RhoGDI2) has been found to be a regulator of tumor metastasis. However, the expression of RhoGDI2 and its clinicopathological significance as well as the pathway of RhoGDI2 in tumor metastasis have yet to be investigated. To investigate the role of RhoGDI2 in the progression and prognosis of pancreatic carcinoma (PC), the expression of RhoGDI2 in human PC tissues was examined and compared with the clinicopathological characteristics and prognosis. Moreover, the relationship between RhoGDI2 and E-cadherin was examined. The results indicated that RhoGDI2 was overexpressed in PC tissues and associated with clinicopathological characteristics, including clinical stage and lymph node metastasis. Patients with a RhoGDI2‑negative expression had a significantly longer survival time than those with a RhoGDI2‑positive expression. Additionally, the expression of RhoGDI2 was negatively correlated with the expression of E-cadherin in PC tissues. Taken together, the findings suggest that RhoGDI2 is important in the progression and prognosis of PC, and may be used as a potential prognostic biomarker and a therapeutic target for PC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011. View Article : Google Scholar : PubMed/NCBI
3	Vega FM and Ridley AJ: Rho GTPases in cancer cell biology. FEBS Lett. 582:2093–2101. 2008. View Article : Google Scholar : PubMed/NCBI
4	Reymond N, Riou P and Ridley AJ: Rho GTPases and cancer cell transendothelial migration. Methods Mol Biol. 827:123–142. 2012. View Article : Google Scholar
5	Garcia-Mata R, Boulter E and Burridge K: The ‘invisible hand’: regulation of RHO GTPases by RHOGDIs. Nat Rev Mol Cell Biol. 12:493–504. 2011. View Article : Google Scholar : PubMed/NCBI
6	Cho HJ, Baek KE and Yoo J: RhoGDI2 as a therapeutic target in cancer. Expert Opin Ther Targets. 14:67–75. 2010. View Article : Google Scholar
7	Agarwal NK, Chen CH, Cho H, Boulbes DR, Spooner E and Sarbassov DD: Rictor regulates cell migration by suppressing RhoGDI2. Oncogene. 32:2521–2526. 2013. View Article : Google Scholar
8	Griner EM and Theodorescu D: The faces and friends of RhoGDI2. Cancer Metastasis Rev. 31:519–528. 2012. View Article : Google Scholar : PubMed/NCBI
9	Yi B, Hu Y, Qin G, et al: Depletion of RhoGDI2 expression inhibits the ability of invasion and migration in pancreatic carcinoma. Int J Mol Med. 34:205–212. 2014.PubMed/NCBI
10	Rhim AD, Mirek ET, Aiello NM, et al: EMT and dissemination precede pancreatic tumor formation. Cell. 148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
11	Kevans D, Wang LM, Sheahan K, et al: Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status. Int J Surg Pathol. 19:751–760. 2011. View Article : Google Scholar : PubMed/NCBI
12	Matsuoka J, Yashiro M, Doi Y, et al: Hypoxia stimulates the EMT of gastric cancer cells through autocrine TGFβ signaling. PLoS One. 8:e623102013. View Article : Google Scholar
13	Burgess DJ: Breast cancer: Circulating and dynamic EMT. Nat Rev Cancer. 13:1482013. View Article : Google Scholar : PubMed/NCBI
14	Nitz MD, Harding MA and Theodorescu D: Invasion and metastasis models for studying RhoGDI2 in bladder cancer. Methods Enzymol. 439:219–233. 2008. View Article : Google Scholar : PubMed/NCBI
15	Li X, Wang J, Zhang X, Zeng Y, Liang L and Ding Y: Overexpression of RhoGDI2 correlates with tumor progression and poor prognosis in colorectal carcinoma. Ann Surg Oncol. 19:145–153. 2012. View Article : Google Scholar
16	Scherle P, Behrens T and Staudt LM: Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes. Proc Natl Acad Sci USA. 90:7568–7572. 1993. View Article : Google Scholar : PubMed/NCBI
17	Niu H, Li H, Xu C and He P: Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis. Oncol Rep. 24:465–471. 2010.PubMed/NCBI
18	Cho HJ, Baek KE, Kim IK, et al: Proteomics-based strategy to delineate the molecular mechanisms of RhoGDI2-induced metastasis and drug resistance in gastric cancer. J Proteome Res. 11:2355–2364. 2012. View Article : Google Scholar : PubMed/NCBI
19	Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM and Frierson HF Jr: Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res. 10:3800–3806. 2004. View Article : Google Scholar : PubMed/NCBI
20	Ma L, Xu G, Sotnikova A, et al: Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma. Br J Haematol. 139:217–223. 2007. View Article : Google Scholar : PubMed/NCBI
21	Dovas A and Couchman JR: RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem J. 390:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
22	DerMardirossian C and Bokoch GM: GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol. 15:356–363. 2005. View Article : Google Scholar : PubMed/NCBI
23	Hart MJ, Maru Y, Leonard D, Witte ON, Evans T and Cerione RA: A GDP dissociation inhibitor that serves as a GTPase inhibitor for the Ras-like protein CDC42Hs. Science. 258:812–815. 1992. View Article : Google Scholar : PubMed/NCBI
24	Chuang TH, Xu X, Knaus UG, Hart MJ and Bokoch GM: GDP dissociation inhibitor prevents intrinsic and GTPase activating protein-stimulated GTP hydrolysis by the Rac GTP-binding protein. J Biol Chem. 268:775–778. 1993.PubMed/NCBI
25	Yilmaz M and Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
26	Theys J, Jutten B, Habets R, et al: E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiother Oncol. 99:392–397. 2011. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Overexpression of RhoGDI2 correlates with the progression and prognosis of pancreatic carcinoma

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles